Page 1 - The Hemophilia Times 2.0_Neat

Breaking News:
QUICK REVISION

HEMLIBRA is a therapeutic bispecific monoclonal antibody
Mr. Clotty has reached Indian shores to redefine hemophilia &

HEMLIBRA is the first and only weekly subcutaneous prophylaxis injection for patients
with Hemophilia found enjoying jet ski.

Safety and tolerability profile is evaluated in largest clinical trial programme in

patients with inhibitors

Compared with BPA on-demand, HEMLIBRA delivered unprecedented bleed protection
(62.9% of patients had zero treated bleeds with HEMLIBRA prophylaxis)

Compared with BPA prior prophylaxis, HEMLIBRA delivered unprecedented bleed protection
(70.8% of patients had zero treated bleeds with HEMLIBRA prophylaxis)

In paediatric patients, HEMLIBRA resulted in substantial bleed protection
(87% of paediatric patients had zero treated bleeds with HEMLIBRA prophylaxis)

HEMLIBRA resulted in clinically meaningful improvements in quality of life

Compared with BPA on-demand, HEMLIBRA resulted in fewer hospitalisations and fewer
missed days of work/school

Any queries to be asked to Mr. Clotty?
………………………………………………………………………………………………………

…………….………………………………………………………………………………………
………………………………………………………………………………………………………
………………………………………………………………………………………………………
………………………………………………………………………………………………………
………………………………………………………………………………………………………

………………………………………………………………………………………………………
………………………………………………………………………………………………………
………………………………………………………………………………………………

For internal use only